Featured
-
-
Review Article |
Nucleic acid-based drugs for patients with solid tumours
Nucleic acid-based therapies offer an alternative to traditional cancer treatment modalities, with promising data beginning to emerge. In this Review, the authors describe the design and development of nucleic acid-based therapies administered virally and non-virally, including discussions of the advantages and disadvantage of each approach, as well as the role of patient-specific factors such as the tumour microenvironment, and consider the most promising future research directions.
- Sebastian G. Huayamares
- , David Loughrey
- & Eric J. Sorscher
-
Research Highlight |
IL-13Rα2-targeted CAR T cells show promise in patients with recurrent high-grade gliomas
- David Killock
-
Review Article |
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Chimeric antigen receptor (CAR) T cells are effective therapies for patients with relapsed and/or refractory B cell malignancies, partly owing to the ability to target B cell-specific antigens. However, CAR T cells targeting solid tumour antigens are likely to carry a higher risk of on-target, off-tumour toxicity (OTOT). Here, the authors summarize the available data on OTOT in the context of CAR T cells targeting solid tumour antigens and describe novel CAR T cell designs that might overcome such toxicities.
- Christian L. Flugel
- , Robbie G. Majzner
- & Mohamed Abou-el-Enein
-
-
-
-
-
-
-
-
-
Review Article |
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy, the first approved therapeutic approach with a genetic engineering component, holds substantial promise in the treatment of a range of cancers but is nevertheless limited by various challenges, including toxicities, intrinsic and acquired resistance mechanisms, and manufacturing issues. In this Review, the authors describe the innovative approaches to the engineering of CAR T cell products that are providing solutions to these challenges and therefore have the potential to considerably improve the safety and effectiveness of treatment.
- Sarwish Rafiq
- , Christopher S. Hackett
- & Renier J. Brentjens
-
-